Navigation Links
Leeds researchers test benefit of fish oil in bowel cancer spread
Date:7/1/2011

Researchers from the University of Leeds will carry out a series of experiments to see whether fish oil can prevent or treat the spread of bowel cancer to the liver.

The cancer scientists will test the effectiveness of pure Eicosapentaenoic Acid (EPA) - a naturally occurring omega-3 fish oil component which is widely available in mixed fish oil preparations in health stores and supermarkets nationwide.

Gastroenterologist Professor Mark Hull, based at the Leeds Institute of Molecular Medicine, University of Leeds, will use results from the initial experiments to design a future clinical trial to test the effect of pure EPA in humans at risk of or with metastatic bowel cancer.

The research is being funded by Yorkshire Cancer Research and it will hopefully back up existing evidence from a previous clinical trial from Leeds that showed that EPA may prevent large bowel polyps, the benign precursors of large bowel cancer.

"We and others have already demonstrated that EPA might have beneficial effects at a later stage after development of malignancy," said Professor Hull.

"These new tests will help us establish whether EPA can prevent the spread of large bowel cancer to the liver, the commonest site of spread and eventual cancer-related death which we call metastasis.

"The tests will also help us establish how EPA reduces growth of established liver metastases in an experimental system prior to design of the clinical trial."

The trial published last year, which involved 55 patients with the rare inherited condition Familial Adenomatous Polyposis (FAP) thought to be responsible for about one in every 100 bowel cancers, saw a significant reduction in the size and number of pre-cancerous growths, known as polyps, in those patients who took a two gram daily dose of EPA in the free fatty acid form over a six month period.

Another promising study currently being led by the Leeds team involving nearly a 1000 patients, is investigating whether taking EPA alone, or together with aspirin, can help stop pre-cancerous growths from developing in the bowel.


'/>"/>

Contact: Paula Gould
p.a.gould@leeds.ac.uk
44-133-343-8059
University of Leeds
Source:Eurekalert

Related medicine news :

1. Leeds Teaching Hospitals Trust and RSLSteeper Team Up to Help Paralympian Walk His Sister Down the Aisle
2. Fox Chase researchers identify new mechanism used by cells to reverse silenced genes
3. BUSM researchers find herbal medicine treatment reduces inflammation in allergen-induced asthma
4. Researchers at Oregon Health & Science University discover MS-like disease in monkeys
5. Drug shows improved kidney function for type 2 diabetics, UT Southwestern researchers report
6. Researchers identify components of speech recognition pathway in humans
7. Wayne State University researchers win grant from the NSF to target tinnitus
8. Researchers find CDT biomarker ineffective for identifying unhealthy alcohol use
9. Mayo Clinic researchers use human vaccine to cure prostate cancer in mice
10. UT Southwestern researchers uncover why ketamine produces a fast antidepressant response
11. Researchers report progress using iPS cells to reverse blindness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne ... signature product of her research center at Bio-Logic Aqua Research® Water Life Science®, ... the greatest number of sufferers of blindness. “We think that Nature’s Tears® EyeMist® ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... may give insight into why concussion rates are on the rise, say researchers ... Annual Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... enterprise-grade IT operations analytics and application performance monitoring (APM) solutions, has expanded ... healthcare services providers. , According to Peter Ohrenberger, sales director at Nastel, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Team Type 1 Foundation, a ... for everyone affected by diabetes, is teaming up with a Microsoft Corp. employee-led hackathon ... off on July 24th. , “Team Type 1’s mission overlaps seamlessly with Microsoft’s ...
(Date:7/20/2017)... ... July 20, 2017 , ... Using CDRH’s Medical Device ... — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/mdqualitydata          , Device makers ... It’s known as the “CY2016 Annual FDA Medical Device Quality System Data” report. ...
Breaking Medicine News(10 mins):
(Date:7/6/2017)... division of Diplomat Specialty Infusion Group, is celebrating a decade of empowering ... celebrate its anniversary, ThriveRx recently launched a redesigned website at thriverx.diplomat.is ... to create the best user experience for consumers and health care professionals. ... Diplomat Pharmacy ... "We,ve made several great strides throughout the past 10 years," ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... a clinical-stage pharmaceutical company focused on the development of oral ... from the Israel Securities Authority to dual-list its common stock ... will commence trading on the TASE on July 12, 2017 ... of the Company, it is expected that Oramed will be ...
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
Breaking Medicine Technology: